Search results for "overgrowth"

showing 10 items of 16 documents

2019

PIK3CA-related overgrowth spectrum (PROS) encompasses a range of debilitating conditions defined by asymmetric overgrowth caused by mosaic activating PIK3CA variants. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), a critical transducer of growth factor signaling. As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth. Thirty-nine participants with PROS and progressive overgrowth were enrolled into open-label studies across three centers, and results were pooled. For the primary outcome, tissue volumes at affected and unaffected sites were measured by dual energy X-ray ab…

0301 basic medicinemedicine.medical_specialtybusiness.industrySirolimus therapyLow doseDiscovery and development of mTOR inhibitorsGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicinePrimary outcome030220 oncology & carcinogenesisSirolimusInternal medicinemedicineAsymmetric overgrowthbusinessAdverse effectPathologicalGenetics (clinical)medicine.drugGenetics in Medicine
researchProduct

Cyclosporin- and nifedipine-induced gingival overgrowth in renal transplant patients: correlations with periodontal and pharmacological parameters, a…

1996

The factors associated with cyclosporin A (CsA)- and nifedipine (Nif)-induced gingival overgrowth were investigated in 113 renal transplant recipients receiving CsA alone (Group 1) [n = 61], CsA and Nif (Group 2) [n = 28], or azathioprine (Aza) (Control Group) [n = 24]. Periodontal and pharmacological parameters were assessed for each patient. The patients with a gingival overgrowth index (GOI) score1 were considered responders (R); those with a score/= 1 were non-responders (NR). Gingival overgrowth occurred in 33.7% of the patients in Groups 1 and 2; 60% of the responders were receiving CsA+Nif. In R, no relationship was found between the GOI and the periodontal and pharmacological parame…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentNifedipineAzathioprineGastroenterologyPathology and Forensic MedicinePathogenesisNifedipineHLA AntigensInternal medicineCyclosporin aAzathioprinePrevalencemedicineHumansPeriodontal PocketDental CalculusChildSalivaKidney transplantationKidneyHLA-A AntigensGingival Overgrowthbusiness.industryDental Plaque IndexMiddle AgedCalcium Channel Blockersmedicine.diseaseGingivitisKidney TransplantationTransplantationEndocrinologymedicine.anatomical_structureOtorhinolaryngologyToxicityCyclosporineIrritantsPeriodonticsFemaleDisease SusceptibilityPeriodontal IndexOral SurgerybusinessImmunosuppressive Agentsmedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin

2009

AIM: To estimate the prevalence of small intestinal bacterial overgrowth (SIBO) in our geographical area (Western Sicily, Italy) by means of an observational study, and to gather information on the use of locally active, non-absorbable antibiotics for treatment of SIBO. METHODS: Our survey included 115 patients fulfilling the Rome II criteria for diagnosis of irritable bowel syndrome (IBS); a total of 97 patients accepted to perform a breath test with lactulose (BTLact), and those who had a positive test, received Rifaximin (Normix®, Alfa Wassermann) 1200 mg/d for 7 d; 3 wk after the end of treatment, the BTLact was repeated. RESULTS: Based on the BTLact results, SIBO was present in about 5…

AdultMalemedicine.medical_specialtyConstipationGastroenterologyRifaximinIrritable Bowel SyndromeLactulosechemistry.chemical_compoundAnti-Infective AgentsGastrointestinal AgentsInternal medicineIntestine SmallSmall intestinal bacterial overgrowthmedicineHumansSicilyIrritable bowel syndromeBreath testSettore MED/12 - GastroenterologiaGastrointestinal agentmedicine.diagnostic_testbusiness.industrydigestive oral and skin physiologyGastroenterologyBacterial InfectionsGeneral Medicinemedicine.diseaseRifamycinsLactuloseRifaximinBrief ArticlesBreath TestschemistryEtiologyFemalemedicine.symptombusinessSIBO rifaximinemedicine.drugWorld Journal of Gastroenterology
researchProduct

Wilms' tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas

2012

Nephroblastoma (Wilms' tumor; WT) is the most common renal tumor of childhood. To date, several genetic abnormalities predisposing to WT have been identified in rare overgrowth syndromes. Among them, abnormal methylation of the 11p15 region, GPC3 and DIS3L2 mutations, which are responsible for Beckwith-Wiedemann, Simpson-Golabi-Behmel and Perlman syndromes, respectively. However, the underlying cause of WT remains unknown in the majority of cases. We report three unrelated patients who presented with WT in addition to a constitutional 9q22.3 microdeletion and dysmorphic/overgrowth syndrome. The size of the deletions was variable (ie, from 1.7 to 8.9 Mb) but invariably encompassed the PTCH1 …

AdultPatched Receptorsmedicine.medical_specialtyPathologyPTCH1AdolescentNonsense mutationCNVShort ReportReceptors Cell SurfaceBiologymedicine.disease_causeWilms’ tumorWilms TumorFetal MacrosomiaSettore MED/38 - Pediatria Generale E SpecialisticaPregnancyInternal medicineGeneticsmedicineHumansPerlman syndromeChildovergrowthGenetics (clinical)MutationComparative Genomic HybridizationWilms' tumorPTCH1 GeneMicrodeletion syndromeFANCC nephroblastomamedicine.diseaseKidney NeoplasmsPatched-1 ReceptorEndocrinologyPTCH1Settore MED/03 - Genetica MedicaOvergrowth syndromeMutationFemaleChromosome DeletionChromosomes Human Pair 9Comparative genomic hybridization
researchProduct

Obstructive sleep apnoea in adult patients post-tonsillectomy

2021

Background: The impact of removing the upper airway lymphoid tissue and in particular, tonsillectomy, in adults with OSA has not been demonstrated in large populations. Aims: To compare the severity of OSA and the prevalence of cardiovascular, metabolic and respiratory co-morbidities between patients with OSA who had undergone previous tonsillectomy and those who had not. Methods: The 19,711 participants in this study came from the European sleep apnea database (ESADA) which comprises data from unselected adult patients aged 18–80 years with a history of symptoms suggestive of OSA referred to sleep centers throughout Europe. Results: There were no differences between the two groups in terms…

AdultPediatricsmedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]ESADALymphoid tissue overgrowthSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesSleep apnoea0302 clinical medicinemedicineHumansMass indexRespiratory systemTonsillectomySleep Apnea ObstructiveAdult patientsbusiness.industrySleep apneaGeneral MedicineESADA ; Lymphoid tissue overgrowth ; Sleep apnoea ; Tonsillectomy.medicine.diseaseSleep in non-human animalsrespiratory tract diseasesTonsillectomy[SDV] Life Sciences [q-bio]Europe030228 respiratory systemDiabetes Mellitus Type 2Lower prevalenceTonsillectomy.AirwaybusinessSleep030217 neurology & neurosurgery
researchProduct

Lymphoproliferative disorders in Sotos syndrome: Observation of two cases

1996

Sotos syndrome is included among the overgrowth disorders, most of which have an increased risk of neoplasms. Sotos syndrome does not appear to be related to a specific tumor type, but rather to the development of solid tumors of ectodermal or mesodermal origin in general. We report on two Sotos syndrome patients who developed a non-Hodgkin lymphoma and an acute lymphoblastic leukaemia, respectively. Our experience suggests that there may exist a high frequency of lymphoproliferative disorders in Sotos syndrome, and points out the importance of a long-term follow-up of Sotos syndrome patients, to detect a possible neoplastic evolution. ©1996 Wiley-Liss, Inc.

MalePathologymedicine.medical_specialtyLymphoproliferative disordersOvergrowth syndromeshemic and lymphatic diseasesmedicineHumansAbnormalities MultipleTumor typeSotos syndromeGrowth DisordersGenetics (clinical)Sotos syndromebusiness.industrySkullBrainSyndromemedicine.diseasePhenotypeLymphoproliferative DisordersLymphomaIncreased riskEl NiñoChild PreschoolLymphoblastic leukaemiabusinessAmerican Journal of Medical Genetics
researchProduct

Hydrogen- and Methane-Based Breath Testing and Outcomes in Patients With Heart Failure

2019

Background: Recent evidence endorses gut microbiota dysregulation in the pathophysiology of heart failure (HF). Small intestinal bacterial overgrowth (SIBO) might be present in HF and associated with poor clinical outcomes. Lactulose breath testing is a simple noninvasive test that has been advocated as a reliable indicator of SIBO. In patients with HF, we aimed to evaluate the association with clinical outcomes of the exhaled hydrogen (H-2) and methane (CH4) concentrations through the lactulose breath test. Methods and Results: We included 102 patients with HF in which lactulose SIBO breath tests were assessed. Cumulative gas was quantified by the area under the receiver operating characte…

Malemedicine.medical_specialtyheart failuresmall intestinal bacterial overgrowth030204 cardiovascular system & hematologyRate ratioGastroenterologyArticle03 medical and health sciencesLactulose0302 clinical medicineInterquartile rangeInternal medicineIntestine SmallSmall intestinal bacterial overgrowthmedicineHumansGutProspective Studies030212 general & internal medicineAgedAged 80 and overHeart FailureBreath testBacteriamedicine.diagnostic_testReceiver operating characteristicbusiness.industryHazard ratiomedicine.diseaseGastrointestinal MicrobiomeHospitalizationBreath TestsExhalationHeart failureFemalebreath testsprognosisCardiology and Cardiovascular MedicinebusinessMethaneFollow-Up StudiesHydrogenmedicine.drug
researchProduct

Abnormal expansion of segmented filamentous bacteria in the gut

2011

Human intestinal microbiota create a complex polymicrobial ecology characterized by high population density, wide diversity, and complexity of interactions. Any imbalance of this complex intestinal microbiome, both qualitative and quantitative, might have serious health consequences including an increase in the number and/or alteration in the type of bacteria in the upper gastrointestinal tract, which is referred to as small intestinal bacterial overgrowth (SIBO) syndrome. SIBO is frequently found in persons fulfilling criteria for irritable bowel syndrome (IBS), and the large overlapping of symptoms of these two pathological conditions led some authors to believe that IBS is secondary to S…

Microbiology (medical)PathogenesisSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/18 - Chirurgia GeneraleHealth consequencesSettore BIO/13 - Biologia ApplicataSegmented filamentous bacteriaEcology (disciplines)Intestinal MicrobiomeChronic intestinal desease overgrowth segmented filamentous bacteriaBiologyMicrobiologyReviews in Medical Microbiology
researchProduct

The child with overgrowth between clinical variability and genetic heterogeneity

2020

Either in the newborn or in the child overgrowth can be generalized or localized if it is limited to one or more body regions. When overgrowth depends on a metabolic imbalance, or it is constitutional, the excessive growth can be the only clinical sign. In most cases genomic or epigenetic alterations, which affect factors involved in cell proliferation and/or regulation of gene expression (observed also in tumours), are related to overgrowth syndromes, in which excess growth may be associated with dysmorphic features, neuromotor/intellectual disabilities and behavioural disorders. These rare conditions are characterized by clinical and molecular overlap. The paper describes the cases of thr…

Segmental overgrowth syndromeGenotype-phenotype correlationNext generation sequencingOncological surveillance
researchProduct

Deletion of NSD1 exon 14 in Sotos syndrome: first description.

2010

Settore MED/38 - Pediatria Generale E SpecialisticaSotos syndromeovergrowthmultiple ligation-dependent probe amplificationhuman genetics.
researchProduct